Switzerland Considers Pilot Scheme for Recreational Cocaine Sales
In a groundbreaking move, Switzerland is exploring a pilot scheme to allow the recreational sale of cocaine, a radical approach to the global war on drugs. While the idea has gained support in the Bern Parliament, it faces opposition from the city government and necessitates a change in national law.
The proposal, still in its early stages, challenges traditional drug policies, especially as Switzerland reconsiders its stance on bans, criticized by some as ineffective. Switzerland has one of the highest levels of cocaine use in Europe, prompting a reevaluation of its drug policies.
Eva Chen, a member of the Bern council, co-sponsored the proposal, stating, "The war on drugs has failed, and we have to look at new ideas. Control and legalization can do better than mere repression."
Wealthy Switzerland's increasing cocaine use, particularly in cities like Zurich, Basel, and Geneva, has led to a reevaluation of drug policies. Cocaine prices have halved in the last five years, according to Addiction Switzerland.
The education, social affairs, and sport directorate in Bern is preparing a report on the potential cocaine trial, emphasizing that it does not guarantee its implementation. The Bern government cautions about the life-threatening nature of cocaine, highlighting the risks of overdose and individual intolerance.
For the trial to proceed, parliamentary amendments to the law prohibiting recreational cocaine use are required. The decision could take years or come earlier if the ongoing cannabis schemes, where the drug is available at pharmacies, show successful results.
Proponents of the pilot scheme advocate for quality controls, information campaigns, and a reduction in the criminal market. While experts are divided on the potential dangers, some argue for a more pragmatic approach to cocaine use, focusing on harm reduction and safe consumption.
The proposal signals a paradigm shift in drug policy, challenging conventional notions and exploring alternative approaches to drug regulation.
